Not all monoclonals are created equal - Lessons from failed drug trials in Crohn's disease

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 3, 2014, Pages 437-449

  Kaser, Arthur ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Crohn's disease

Indexed keywords

ABATACEPT; ADALIMUMAB; BRIAKINUMAB; BRODALUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; FONTOLIZUMAB; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; MONOCLONAL ANTIBODY; SECUKINUMAB; USTEKINUMAB; VEDOLIZUMAB;

ARTICLE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; PSORIASIS; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

CLINICAL TRIALS; CROHN'S DISEASE;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; CYTOKINES; HUMANS; TREATMENT FAILURE;

EID: 84902266081     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.04.005     Document Type: Review

References (104)

1. W.J. Sandborn, B.G. Feagan, P. Rutgeerts, S. Hanauer, J.F. Colombel, and B.E. Sands et al. Vedolizumab as induction and maintenance therapy for Crohn's disease N Engl J Med 369 2013 711 721
2. B.G. Feagan, P. Rutgeerts, B.E. Sands, S. Hanauer, J.F. Colombel, and W.J. Sandborn et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 2013 699 710
3. T. Lobaton, S. Vermeire, G. Van Assche, and P. Rutgeerts Review article: anti-adhesion therapies for inflammatory bowel disease Aliment Pharmacol Ther 39 2014 579 594
4. W.J. Sandborn, J.F. Colombel, R. Enns, B.G. Feagan, S.B. Hanauer, and I.C. Lawrance et al. Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 2005 1912 1925
5. S.R. Targan, B.G. Feagan, R.N. Fedorak, B.A. Lashner, R. Panaccione, and D.H. Present et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial Gastroenterology 132 2007 1672 1683
6. G. Van Assche, M. Van Ranst, R. Sciot, B. Dubois, S. Vermeire, and M. Noman et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease N Engl J Med 353 2005 362 368
7. B. Derkx, J. Taminiau, S. Radema, A. Stronkhorst, C. Wortel, and G. Tytgat et al. Tumour-necrosis-factor antibody treatment in Crohn's disease Lancet 342 1993 173 174
8. A. Kaser, S. Zeissig, and R.S. Blumberg Inflammatory bowel disease Annu Rev Immunol 28 2010 573 621
9. C. Abraham, and J.H. Cho Inflammatory bowel disease N Engl J Med 361 2009 2066 2078
10. K.J. Maloy, and F. Powrie Intestinal homeostasis and its breakdown in inflammatory bowel disease Nature 474 2011 298 306
11. J. Halfvarson, L. Bodin, C. Tysk, E. Lindberg, and G. Jarnerot Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics Gastroenterology 124 2003 1767 1773
12. L. Halme, P. Paavola-Sakki, U. Turunen, M. Lappalainen, M. Farkkila, and K. Kontula Family and twin studies in inflammatory bowel disease World J Gastroenterol 12 2006 3668 3672
13. M. Orholm, V. Binder, T.I. Sorensen, L.P. Rasmussen, and K.O. Kyvik Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study Scand J Gastroenterol 35 2000 1075 1081
14. L. Jostins, S. Ripke, R.K. Weersma, R.H. Duerr, D.P. McGovern, and K.Y. Hui et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease Nature 491 2012 119 124
15. M. Parkes, A. Cortes, D.A. van Heel, and M.A. Brown Genetic insights into common pathways and complex relationships among immune-mediated diseases Nat Rev Genet 14 2013 661 673
16. S.H. Murch, V.A. Lamkin, M.O. Savage, J.A. Walker-Smith, and T.T. MacDonald Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease Gut 32 1991 913 917
17. C.P. Braegger, S. Nicholls, S.H. Murch, S. Stephens, and T.T. MacDonald Tumour necrosis factor alpha in stool as a marker of intestinal inflammation Lancet 339 1992 89 91
18. W.E. Pullman, S. Elsbury, M. Kobayashi, A.J. Hapel, and W.F. Doe Enhanced mucosal cytokine production in inflammatory bowel disease Gastroenterology 102 1992 529 537
19. D. Kontoyiannis, M. Pasparakis, T.T. Pizarro, F. Cominelli, and G. Kollias Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies Immunity 10 1999 387 398
20. J.F. Colombel, W.J. Sandborn, W. Reinisch, G.J. Mantzaris, A. Kornbluth, and D. Rachmilewitz et al. Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
21. P. Rutgeerts, S. Vermeire, and G. Van Assche Biological therapies for inflammatory bowel diseases Gastroenterology 136 2009 1182 1197
22. K.M. Mohler, D.S. Torrance, C.A. Smith, R.G. Goodwin, K.E. Stremler, and V.P. Fung et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists J Immunol 151 1993 1548 1561
23. Z. Kaymakcalan, P. Sakorafas, S. Bose, S. Scesney, L. Xiong, and D.K. Hanzatian et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor Clin Immunol 131 2009 308 316
24. D. Shealy, A. Cai, K. Staquet, A. Baker, E.R. Lacy, and L. Johns et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha MAbs 2 2010
25. L.W. Moreland, S.W. Baumgartner, M.H. Schiff, E.A. Tindall, R.M. Fleischmann, and A.L. Weaver et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N Engl J Med 337 1997 141 147
26. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang et al. Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
27. P.J. Mease, B.S. Goffe, J. Metz, A. VanderStoep, B. Finck, and D.J. Burge Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 2000 385 390
28. J.D. Gorman, K.E. Sack, and J.C. Davis Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha N Engl J Med 346 2002 1349 1356
29. W.J. Sandborn, S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, and R.D. Baerg et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
30. S.T. Peake, D. Bernardo, E.R. Mann, H.O. Al-Hassi, S.C. Knight, and A.L. Hart Mechanisms of action of anti-tumor necrosis factor alpha agents in Crohn's disease Inflamm Bowel Dis 19 2013 1546 1555
31. A.C. Vos, M.E. Wildenberg, M. Duijvestein, A.P. Verhaar, G.R. van den Brink, and D.W. Hommes Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner Gastroenterology 140 2011 221 230
32. J.M. Van den Brande, H. Braat, G.R. van den Brink, H.H. Versteeg, C.A. Bauer, and I. Hoedemaeker et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 2003 1774 1785
33. A. Lugering, M. Schmidt, N. Lugering, H.G. Pauels, W. Domschke, and T. Kucharzik Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway Gastroenterology 121 2001 1145 1157
34. T.T. Macdonald Inside the microbial and immune labyrinth: totally gutted Nat Med 16 2010 1194 1195
35. R. Atreya, H. Neumann, C. Neufert, M.J. Waldner, U. Billmeier, and Y. Zopf et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease Nat Med 20 2014 313 318
36. S. Fais, M.R. Capobianchi, M. Silvestri, F. Mercuri, F. Pallone, and F. Dianzani Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells J Interferon Res 14 1994 235 238
37. I.J. Fuss, M. Neurath, M. Boirivant, J.S. Klein, C. de la Motte, and S.A. Strong et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5 J Immunol 157 1996 1261 1270
38. W. Strober, and I.J. Fuss Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases Gastroenterology 140 2011 1756 1767
39. W. Reinisch, D.W. Hommes, G. Van Assche, J.F. Colombel, J.P. Gendre, and B. Oldenburg et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease Gut 55 2006 1138 1144
40. D.W. Hommes, T.L. Mikhajlova, S. Stoinov, D. Stimac, B. Vucelic, and J. Lonovics et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease Gut 55 2006 1131 1137
41. W. Reinisch, W. de Villiers, L. Bene, L. Simon, I. Racz, and S. Katz et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study Inflamm Bowel Dis 16 2010 233 242
42. P.J. Mannon, I.J. Fuss, L. Mayer, C.O. Elson, W.J. Sandborn, and D. Present et al. Anti-interleukin-12 antibody for active Crohn's disease N Engl J Med 351 2004 2069 2079
43. W.J. Sandborn, B.G. Feagan, R.N. Fedorak, E. Scherl, M.R. Fleisher, and S. Katz et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 2008 1130 1141
44. W.J. Sandborn, C. Gasink, L.L. Gao, M.A. Blank, J. Johanns, and C. Guzzo et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease N Engl J Med 367 2012 1519 1528
45. D.A. Vignali, and V.K. Kuchroo IL-12 family cytokines: immunological playmakers Nat Immunol 13 2012 722 728
46. M.F. Neurath, I. Fuss, B.L. Kelsall, E. Stuber, and W. Strober Antibodies to interleukin 12 abrogate established experimental colitis in mice J Exp Med 182 1995 1281 1290
47. G. Monteleone, L. Biancone, R. Marasco, G. Morrone, O. Marasco, and F. Luzza et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells Gastroenterology 112 1997 1169 1178
48. P. Parronchi, P. Romagnani, F. Annunziato, S. Sampognaro, A. Becchio, and L. Giannarini et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease Am J Pathol 150 1997 823 832
49. S. Hue, P. Ahern, S. Buonocore, M.C. Kullberg, D.J. Cua, and B.S. McKenzie et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation J Exp Med 203 2006 2473 2483
50. H.H. Uhlig, B.S. McKenzie, S. Hue, C. Thompson, B. Joyce-Shaikh, and R. Stepankova et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology Immunity 25 2006 309 318
51. K. Reich, R.G. Langley, K.A. Papp, J.P. Ortonne, K. Unnebrink, and M. Kaul et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis N Engl J Med 365 2011 1586 1596
52. C.E. Griffiths, B.E. Strober, P. van de Kerkhof, V. Ho, R. Fidelus-Gort, and N. Yeilding et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
53. I. Cleynen, and S. Vermeire Paradoxical inflammation induced by anti-TNF agents in patients with IBD Nat Rev Gastroenterol Hepatol 9 2012 496 503
54. C. Tillack, L.M. Ehmann, M. Friedrich, R.P. Laubender, P. Papay, and H. Vogelsang et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma- expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment Gut 63 4 2014 Apr 567 577 10.1136/gutjnl-2012-302853
55. U. Chaudhari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker, and A.B. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial Lancet 357 2001 1842 1847
56. A. Franke, D.P. McGovern, J.C. Barrett, K. Wang, G.L. Radford-Smith, and T. Ahmad et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci Nat Genet 42 2010 1118 1125
57. F. Capon, P. Di Meglio, J. Szaub, N.J. Prescott, C. Dunster, and L. Baumber et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis Hum Genet 122 2007 201 206
58. M.F. Neurath IL-12 family members in experimental colitis Mucosal Immunol 1 Suppl. 1 2008 S28 S30
59. R.S. Blumberg, L.J. Saubermann, and W. Strober Animal models of mucosal inflammation and their relation to human inflammatory bowel disease Curr Opin Immunol 11 1999 648 656
60. T. Korn, E. Bettelli, M. Oukka, and V.K. Kuchroo IL-17 and Th17 cells Annu Rev Immunol 27 2009 485 517
61. S. Fujino, A. Andoh, S. Bamba, A. Ogawa, K. Hata, and Y. Araki et al. Increased expression of interleukin 17 in inflammatory bowel disease Gut 52 2003 65 70
62. V. Holtta, P. Klemetti, T. Sipponen, M. Westerholm-Ormio, G. Kociubinski, and H. Salo et al. IL-23/IL-17 immunity as a hallmark of Crohn's disease Inflamm Bowel Dis 14 2008 1175 1184
63. W. Hueber, D.D. Patel, T. Dryja, A.M. Wright, I. Koroleva, and G. Bruin et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis Sci Transl Med 2 2010 52ra72
64. K.A. Papp, C. Leonardi, A. Menter, J.P. Ortonne, J.G. Krueger, and G. Kricorian et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis N Engl J Med 366 2012 1181 1189
65. S.R. Targan A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease Gastroenterology 142 2012
66. W. Hueber, B.E. Sands, S. Lewitzky, M. Vandemeulebroecke, W. Reinisch, and P.D. Higgins et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial Gut 61 2012 1693 1700
67. T. Raine, and A. Kaser Seventeen in Crohn's disease: less prime than we thought? Gut 61 2012 1653 1654
68. J.F. Colombel, B. Sendid, T. Jouault, and D. Poulain Secukinumab failure in Crohn's disease: the yeast connection? Gut 62 2013 800 801
69. A. Puel, S. Cypowyj, J. Bustamante, J.F. Wright, L. Liu, and H.K. Lim et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity Science 332 2011 65 68
70. D. Poulain, B. Sendid, A. Standaert-Vitse, C. Fradin, T. Jouault, and S. Jawhara et al. Yeasts: neglected pathogens Dig Dis 27 Suppl. 1 2009 104 110
71. A. Standaert-Vitse, T. Jouault, P. Vandewalle, C. Mille, M. Seddik, and B. Sendid et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease Gastroenterology 130 2006 1764 1775
72. T. Schaffer, S. Muller, B. Flogerzi, B. Seibold-Schmid, A.M. Schoepfer, and F. Seibold Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans Inflamm Bowel Dis 13 2007 1339 1346
73. A. Standaert-Vitse, B. Sendid, M. Joossens, N. Francois, P. Vandewalle-El Khoury, and J. Branche et al. Candida albicans colonization and ASCA in familial Crohn's disease Am J Gastroenterol 104 2009 1745 1753
74. I.D. Iliev, V.A. Funari, K.D. Taylor, Q. Nguyen, C.N. Reyes, and S.P. Strom et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis Science 336 2012 1314 1317
75. K.A. Papp, R.G. Langley, B. Sigurgeirsson, M. Abe, D.R. Baker, and P. Konno et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study Br J Dermatol 168 2013 412 421
76. C. Leonardi, R. Matheson, C. Zachariae, G. Cameron, L. Li, and E. Edson-Heredia et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis N Engl J Med 366 2012 1190 1199
77. A. Ogawa, A. Andoh, Y. Araki, T. Bamba, and Y. Fujiyama Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice Clin Immunol 110 2004 55 62
78. W. O'Connor Jr., M. Kamanaka, C.J. Booth, T. Town, S. Nakae, and Y. Iwakura et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation Nat Immunol 10 2009 603 609
79. X.O. Yang, S.H. Chang, H. Park, R. Nurieva, B. Shah, and L. Acero et al. Regulation of inflammatory responses by IL-17F J Exp Med 205 2008 1063 1075
80. Z. Zhang, M. Zheng, J. Bindas, P. Schwarzenberger, and J.K. Kolls Critical role of IL-17 receptor signaling in acute TNBS-induced colitis Inflamm Bowel Dis 12 2006 382 388
81. D. Yen, J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, and B. McKenzie et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6 J Clin Invest 116 2006 1310 1316
82. L. Mayer, A. Kaser, and R.S. Blumberg Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease Gastroenterology 143 2012 13 17
83. M.C. Genovese, J.C. Becker, M. Schiff, M. Luggen, Y. Sherrer, and J. Kremer et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition N Engl J Med 353 2005 1114 1123
84. P. Mease, M.C. Genovese, G. Gladstein, A.J. Kivitz, C. Ritchlin, and P.P. Tak et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial Arthritis Rheum 63 2011 939 948
85. W.J. Sandborn, J.F. Colombel, B.E. Sands, P. Rutgeerts, S.R. Targan, and R. Panaccione et al. Abatacept for Crohn's disease and ulcerative colitis Gastroenterology 143 2012 62-9 e4
86. J.E. Smith-Garvin, G.A. Koretzky, and M.S. Jordan T cell activation Annu Rev Immunol 27 2009 591 619
87. E.C. Ebert, and A.I. Roberts Costimulation of the CD3 pathway by CD28 ligation in human intestinal lymphocytes Cell Immunol 171 1996 211 216
88. D.L. Boone, T. Dassopoulos, J.P. Lodolce, S. Chai, M. Chien, and A. Ma Interleukin-2-deficient mice develop colitis in the absence of CD28 costimulation Inflamm Bowel Dis 8 2002 35 42
89. T. Griseri, M. Asquith, C. Thompson, and F. Powrie OX40 is required for regulatory T cell-mediated control of colitis J Exp Med 207 2010 699 709
90. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
91. A. Izcue, J.L. Coombes, and F. Powrie Regulatory lymphocytes and intestinal inflammation Annu Rev Immunol 27 2009 313 338
92. I. Tiede, G. Fritz, S. Strand, D. Poppe, R. Dvorsky, and D. Strand et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes J Clin Invest 111 2003 1133 1145
93. J. Panes, A. Lopez-Sanroman, F. Bermejo, V. Garcia-Sanchez, M. Esteve, and Y. Torres et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease Gastroenterology 145 2013 766-74 e1
94. J. Cosnes, A. Bourrier, D. Laharie, S. Nahon, Y. Bouhnik, and F. Carbonnel et al. Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial Gastroenterology 145 2013 758-65 e2; quiz e14-e15
95. L. Peyrin-Biroulet, W. Reinisch, J.F. Colombel, G.J. Mantzaris, A. Kornbluth, and R. Diamond et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial Gut 63 2014 88 95
96. S. Danese New therapies for inflammatory bowel disease: from the bench to the bedside Gut 61 2012 918 932
97. S. Raychaudhuri, R.M. Plenge, E.J. Rossin, A.C. Ng, S.M. Purcell, and P. Sklar et al. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions PLoS Genet 5 2009 e1000534
98. Y. Okada, D. Wu, G. Trynka, T. Raj, C. Terao, and K. Ikari et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery Nature 506 2014 376 381
99. J. Hampe, A. Franke, P. Rosenstiel, A. Till, M. Teuber, and K. Huse et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 Nat Genet 39 2007 207 211
100. A. Murthy, Y. Li, I. Peng, M. Reichelt, A.K. Katakam, and R. Noubade et al. A Crohn's disease variant in Atg16l1 enhances its degradation by caspase 3 Nature 506 2014 456 462
101. T.E. Adolph, M.F. Tomczak, L. Niederreiter, H.J. Ko, J. Bock, and E. Martinez-Naves et al. Paneth cells as a site of origin for intestinal inflammation Nature 503 2013 272 276
102. J.J. Deuring, G.M. Fuhler, S.R. Konstantinov, M.P. Peppelenbosch, E.J. Kuipers, and C. de Haar et al. Genomic ATG16L1 risk allele-restricted Paneth cell ER stress in quiescent Crohn's disease Gut 2013 10.1136/gutjnl-2012-303527
103. A. Kaser, and R.S. Blumberg ATG16L1 Crohn's disease risk stresses the endoplasmic reticulum of Paneth cells Gut 2013 10.1136/gutjnl-2013-306103
104. A. Kaser, and R.S. Blumberg Cell biology: stressful genetics in Crohn's disease Nature 506 2014 441 442